Extended data:
Lin Haotian, male, Han nationality, 198 10, born in June, party member, Ph.D., chief physician, doctoral supervisor, leading talent of National Science and Technology Innovation Thousand Talents Program, chief scientist of National Key R&D Project, young and middle-aged experts with outstanding contributions from China and National Health Commission, and leading scientific and technological innovation figure of Guangdong Special Support Program.
Leader of artificial intelligence and big data discipline in Zhongshan Eye Center, Sun Yat-sen University; Completed the world's first real-world research on multi-disease artificial intelligence in ophthalmology, and related research was published online in The Lancet-Digital Health in August, 20021.
He is currently the director of Zhongshan Ophthalmology Center of Sun Yat-sen University, the director of the Department of Genetics and Biomedical Informatics of Sun Yat-sen Medical College of Sun Yat-sen University, the leader of medical artificial intelligence and big data, and the doctoral supervisor of ophthalmology and biomedical engineering; All-china youth federation, member of the Standing Committee and vice chairman of Guangdong Youth Federation.
Lin Haotian, a professor at Zhongshan Ophthalmology Center of Sun Yat-sen University, led Beijing Yingtong Technology Development Co., Ltd., Guangdong Medical Device Quality Supervision and Inspection Institute and other 18 teams of medical, enterprise and scientific research institutions at home and abroad, and made a major breakthrough in the clinical research of ophthalmology. It took three years to complete the world's first real-world research on multi-disease artificial intelligence in ophthalmology. Related research was published online in The Lancet-Digital Health in August, 20021.
At the same time, the director of the Imaging Diagnosis Center of the University of Wisconsin in the United States evaluated this research as "marking the correct development direction of medical artificial intelligence research". It is reported that the greatest significance of this study is that the accuracy of artificial intelligence software has been verified for the first time in a large-scale real-world study of ophthalmology.
At present, the project team has owned a series of technical patents, and obtained the first class III medical device registration certificate of ophthalmic artificial intelligence software issued by the State Medical Products Administration.